ProQR Therapeutics NV (PRQR) EUR0.04

Sell:$2.01Buy:$2.30$0.05 (2.22%)

Prices delayed by at least 15 minutes
Sell:$2.01
Buy:$2.30
Change:$0.05 (2.22%)
Deal now
Prices delayed by at least 15 minutes
Sell:$2.01
Buy:$2.30
Change:$0.05 (2.22%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Key people

Daniel Anton De Boer
Chief Executive Officer, Founder, Executive Director
Jurriaan Dekkers
Chief Financial Officer
Sheila Sponselee
Chief People and Operations Officer
Gerard Platenburg
Chief Scientific Officer, Executive Director
Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
James Samuel Shannon
Independent Non-Executive Chairman of the Board
Dinko Valerio
Non-Executive Director
Begona Carreno
Non-Executive Independent Director
Bart Filius
Non-Executive Independent Director
Theresa M. Heggie
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Netherlands
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    NL0010872495
  • Market cap
    $223.38m
  • Employees
    157
  • Shares in issue
    105.90m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.